drugset / Trial / NCT07153835
Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study
Phase 4
Not yet recruiting
505 enrolled
Sher-E-Bangla Medical College
ACI Pharmaceuticals · collabDr. M M Jalal Uddin · collabDr.Ahsan Aziz Sarkar · collabUS-Bangla Medical College Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter, prospective quasi-experimental study evaluating the efficacy and safety of extended-release paliperidone in adults with schizophrenia in Bangladesh. The study will assess psychotic symptom improvement using the PANSS scale, monitor side effects using GASS, and evaluate quality of life via WHOQOL-BREF.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-03-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone | Unknown | 6 mg | Oral |
| Subject | Paliperidone | Unknown | 12 mg | Oral |